Zkusit zdarma
argenx SE

argenx SE

ARGX
Cena:
$ 806.46
-9.76 (-1.20%)
Valuace
48
Růst
100
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

15:40 12-05-2026

argenx SE (ARGX) Presents at Bank of America Global Healthcare Conference 2026 Transcript...

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

17:20 08-05-2026

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult pa...

argenx SE (ARGX) Q1 2026 Earnings Call Transcript

argenx SE (ARGX) Q1 2026 Earnings Call Transcript

17:11 07-05-2026

argenx SE (ARGX) Q1 2026 Earnings Call Transcript...

argenx to Present at BofA Securities 2026 Health Care Conference

argenx to Present at BofA Securities 2026 Health Care Conference

16:30 06-05-2026

May 6, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology com...

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026

1:00 30-04-2026

April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology ...

Mirae Asset Global Investments Co. Ltd. Buys 2,018 Shares of argenex SE $ARGX

Mirae Asset Global Investments Co. Ltd. Buys 2,018 Shares of argenex SE $ARGX

5:16 20-04-2026

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of argenex SE (NASDAQ: ARGX) by 2...

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

1:00 18-04-2026

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that V...

argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

3:28 12-04-2026

Shares of argenex SE (NASDAQ: ARGX - Get Free Report) have earned a consensus rating of "Moderate Bu...

SG Americas Securities LLC Has $2.67 Million Stock Holdings in argenex SE $ARGX

SG Americas Securities LLC Has $2.67 Million Stock Holdings in argenex SE $ARGX

5:01 04-04-2026

SG Americas Securities LLC increased its stake in argenex SE (NASDAQ: ARGX) by 94.9% during the four...

Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX

Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX

3:22 31-03-2026

Allspring Global Investments Holdings LLC trimmed its position in shares of argenex SE (NASDAQ: ARGX...

eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency

eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency

9:00 24-03-2026

BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and...

Alkeon Capital Management LLC Grows Stock Position in argenex SE $ARGX

Alkeon Capital Management LLC Grows Stock Position in argenex SE $ARGX

3:28 15-03-2026

Alkeon Capital Management LLC grew its holdings in argenex SE (NASDAQ: ARGX) by 133.3% in the undefi...

argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference

argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference

1:32 05-03-2026

argenx (NASDAQ: ARGX) used a fireside chat at the TD Cowen Health Care Conference to outline its nea...

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 6,782 Shares of argenex SE $ARGX

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 6,782 Shares of argenex SE $ARGX

6:54 20-02-2026

BNP PARIBAS ASSET MANAGEMENT Holding S.A. reduced its holdings in argenex SE (NASDAQ: ARGX) by 7.8% ...

Fiera Capital Corp Boosts Stock Position in argenex SE $ARGX

Fiera Capital Corp Boosts Stock Position in argenex SE $ARGX

6:10 20-02-2026

Fiera Capital Corp raised its holdings in argenex SE (NASDAQ: ARGX) by 12.1% during the third quarte...

Aberdeen Group plc Trims Stock Holdings in argenex SE $ARGX

Aberdeen Group plc Trims Stock Holdings in argenex SE $ARGX

3:16 16-02-2026

Aberdeen Group plc lowered its stake in shares of argenex SE (NASDAQ: ARGX) by 5.1% during the third...

Alta Wealth Advisors LLC Makes New $623,000 Investment in argenex SE $ARGX

Alta Wealth Advisors LLC Makes New $623,000 Investment in argenex SE $ARGX

3:38 27-01-2026

Alta Wealth Advisors LLC purchased a new stake in argenex SE (NASDAQ: ARGX) during the third quarter...

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

1:00 13-01-2026

January 13, 2026, 7:00 AM CET  Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), ...

argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

14:06 12-01-2026

argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript...

argenx Highlights 2026 Strategic Priorities

argenx Highlights 2026 Strategic Priorities

1:00 12-01-2026

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales,...

close

ARGENX ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW FOR VYVGART IN ACHR-AB SERONEGATIVE GMG

13-01-2026
JANUARY 13, 2026, 7:00 AM CET  AMSTERDAM, THE NETHERLANDS – ARGENX SE (EURONEXT & NASDAQ: ARGX), ...
Více zde

ARGENX HIGHLIGHTS 2026 STRATEGIC PRIORITIES

12-01-2026
REPORTED $4.15 BILLION (YOY GROWTH OF +90%) IN PRELIMINARY* FULL-YEAR 2025 GLOBAL PRODUCT NET SALES,...
Více zde

ARGENX TO PRESENT AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

06-01-2026
JANUARY 6, 2026 AMSTERDAM, THE NETHERLANDS – ARGENX (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGY...
Více zde

ARGENX ANNOUNCES LEADERSHIP TRANSITION MARKING NEXT EVOLUTION OF GROWTH

05-01-2026
TIM VAN HAUWERMEIREN TO TRANSITION FROM CEO TO NON-EXECUTIVE DIRECTOR AND CHAIRMAN OF BOARD OF DIREC...
Více zde

ARGENX PROVIDES UPDATE ON UPLIGHTED STUDIES OF EFGARTIGIMOD SC IN THYROID EYE DISEASE

15-12-2025
15 DECEMBER, 2025, 7:00 AM CET AMSTERDAM, THE NETHERLANDS – ARGENX SE (EURONEXT & NASDAQ: ARGX), A...
Více zde

ARGENX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

30-10-2025
$1.13 BILLION IN THIRD QUARTER GLOBAL PRODUCT NET SALES  ON TRACK TO SUBMIT SERONEGATIVE GMG SBLA B...
Více zde

ARGENX PRESENTS NEW DATA AT AANEM AND MGFA HIGHLIGHTING THE STRENGTH AND BROAD BENEFIT OF VYVGART FOR MYASTHENIA GRAVIS PATIENTS

29-10-2025
VYVGART DEMONSTRATED CLINICALLY MEANINGFUL BENEFIT ACROSS ALL ACHR-AB SERONEGATIVE GMG SUBTYPES IN A...
Více zde

ARGENX TO HIGHLIGHT KEY DATA AND BREADTH OF IMMUNOLOGY INNOVATION AT 2025 AANEM ANNUAL MEETING AND MGFA SCIENTIFIC SESSION

15-10-2025
PIVOTAL ADAPT SERON RESULTS AND INTERIM ADAPT JR DATA SHOWCASE VYVGART'S POTENTIAL TO TREAT BROAD SE...
Více zde

ARGENX ANNOUNCES EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON NOVEMBER 18, 2025

03-10-2025
OCTOBER 3, 2025 AMSTERDAM, THE NETHERLANDS – ARGENX SE (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOL...
Více zde

FUJIFILM BIOTECHNOLOGIES EXPANDS STRATEGIC PARTNERSHIP WITH ARGENX TO INCLUDE U.S. MANUFACTURING OPERATIONS

18-09-2025
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM BIOTECHNOLOGIES, A WORLD-LEADING CONTRACT DEVELOPMENT...
Více zde

ARGENX TO PRESENT AT UPCOMING INVESTOR CONFERENCES

28-08-2025
AUGUST 28, 2025 AMSTERDAM, THE NETHERLANDS – ARGENX (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGY...
Více zde

ARGENX ANNOUNCES POSITIVE TOPLINE RESULTS FROM ADAPT SERON STUDY OF VYVGART IN PATIENTS WITH ACHR-AB SERONEGATIVE GMG

25-08-2025
STUDY MET PRIMARY ENDPOINT (P-VALUE=0.0068) FIRST GLOBAL PHASE 3 STUDY TO DEMONSTRATE CLINICALLY MEA...
Více zde

ARGENX TO HOST R&D WEBINAR HIGHLIGHTING ARGX-119 ON SEPTEMBER 16, 2025

19-08-2025
AUGUST 19, 2025 AMSTERDAM, THE NETHERLANDS – ARGENX (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGY...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

17-08-2025
NEW YORK, AUG. 17, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

16-08-2025
NEW YORK , AUG. 16, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

13-08-2025
NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

ARGENX AND TENNIS LEGEND MONICA SELES TEAM UP TO RAISE AWARENESS OF MYASTHENIA GRAVIS

12-08-2025
SELES SPEAKS OUT ABOUT HER DIAGNOSIS WITH MG, A CHRONIC AUTOIMMUNE DISEASE THAT CAUSES MUSCLE WEAKNE...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

11-08-2025
NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

09-08-2025
NEW YORK, AUG. 09, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

06-08-2025
NEW YORK , AUG. 6, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

31-07-2025
NEW YORK , JULY 31, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

ARGENX REPORTS HALF YEAR 2025 FINANCIAL RESULTS AND PROVIDES SECOND QUARTER BUSINESS UPDATE

31-07-2025
$949 MILLION IN SECOND QUARTER GLOBAL PRODUCT NET SALES VYVGART SC LAUNCH IN CIDP PROGRESSES WITH MO...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

28-07-2025
NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

27-07-2025
NEW YORK , JULY 27, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

ARGENX TO REPORT HALF YEAR 2025 FINANCIAL RESULTS AND SECOND QUARTER BUSINESS UPDATE ON JULY 31, 2025

24-07-2025
JULY 24, 2025 AMSTERDAM, THE NETHERLANDS – ARGENX (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGY C...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

23-07-2025
NEW YORK, JULY 23, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVES...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

22-07-2025
NEW YORK , JULY 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

17-07-2025
NEW YORK , JULY 17, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

12-07-2025
NEW YORK , JULY 12, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ARGENX SE - ARGX

07-07-2025
NEW YORK , JULY 7, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS...
Více zde

close

Dokumenty nejsou k dispozici

preloader